Empagliflozin, soluble in DMSO and insoluble in ethanol and water, is a sodium-glucose cotransporter inhibitor, preventing the kidneys from reabsorbing glucose. It targets SGLT1, SGLT2, SGLT4, SGLT5, and SGLT6.
Empagliflozin is a SGLT2 inhibitor that is extensively researched for its effects on glucose reabsorption and potential benefits in managing diabetes.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.